February 27, 2015
Volume 19, Issue 9
Hotline # (410) 528-1804
MAKING THE MOST OF YOUR MONEYLETTER SUBSCRIPTION MLP T. Rowe Price Portfolio Current Asset Allocations Bond 20% Domes tic Stock 50%
Money Funds 10%
Int'l Stock 20%
2015 MONEYLETTER Publishing Schedule: Upcoming Issues Issue
Web Post (12p ET Wed)
Maildate (Fri)
March 2015
Mar 4
Mar 6
April 2015
April 8
Apr 10
Top 5 Funds YTD All Categories Year-to-Date Ticker
Fund
Through 2/20/15
1 XBI
SPDR S&P Biotech
14.4%
2 ESR
iShares MSCI Emerging Markets Eastern Europe
13.9
3 PJP
PowerShares Dynamic Pharmaceuticals
13.4
4 FSDAX Fidelity Select Defense & Aerospace
11.6
5 FBIOX Fidelity Select Biotechnology
11.5
MLP T. Rowe Price Model 1/31/15
Purchase Return Shares Share Date Since Price Buy TRP T-E MF TRP Blue Chip 9/30/13 23.4% Growth (TRBCX) TRP Diversi1/24/14 7.5 fied SC Growth (PRDSX) TRP Growth 10/31/14 0.5 Stock (PRGFX) TRP Equity 4/21/14 1.5 Income (PRFDX) TRP Global 7/7/14 -1.2 Stock (PRGSX) TRP Emerging 7/11/14 -5.3 Markets Bond (PREMX) TRP Strategic 9/30/13 6.8 Income (PRSNX) TRP Floating 9/30/13 3.4 Rate (PRFRX) TOTAL VALUE ** Inception = 9/30/13
TOTAL RETURNS (as of 1/31/15)
Value
2500
$1.00
$2,500
69
67.34
4,626
171
25.43
4,351
57
51.88
2,973
83
31.51
2,630
111
25.27
2,806
215
12.06
2,592
237
11.27
2,670
246
9.88
2,431 $27,579
1Month
6Month
1Year
3Year
YTD
-0.4%
1.8%
4.9%
n/a
-0.4%
ETF CORNER
ML Plus Select ETF Model Current Holdings ICF 20%
PBE 20%
PJP 20%
QQQ 20%
EPI 20% MLP Select ETF Model
ML Plus Select ETF Commentary
1/31/15
Based on an update of our “Fund Scorecard & Recommendations,” which include closing market prices through February 25th, there were no fund exchanges recommended. As market indices continue to flirt with record levels we seem to have fallen into a range-bound pattern. Continued volatility in the energy sector -- along with a mixed bag of economic data -- has kept the outlook for global growth muted, leaving investors running in place. While in Congressional testimony Fed Chairman Yellen continues to assert that interest rates will remain low, pundits are left to debate the significance of a possible elimination of the word “patient” in the Fed’s guidance. As we come to month-end we will examine rebalancing transactions, particularly in light of the continued strength of the Biotech and Pharmaceutical sectors. Those sectors and model positions have again led weekly performance, with PowerShares Dynamic Biotech & Genome (PBE) and PowerShares Dynamic Pharmaceuticals (PJP) advancing 3.09% and 1.53% respectively.
Fund
PRI Financial Advisors ♦
Toll-Free: (800) 707-2060
9 $1.00
$9
PowerShares Dynamic Biotech & Genome (PBE)
10/17/14 16.3% 1,171 52.97
62,028
PowerShares QQQ (QQQ)
10/17/14
571 101.10
57,731
WisdomTree India Earnings (EPI)
1/30/15
0.0 2,291 23.45
53,724
9.1
PowerShares 10/03/14 Dynamic Pharmaceuticals (PJP)
12.5
826 70.15
57,948
iShares Cohen & Steers REIT (ICF)
18.6
611 103.83
63,431
10/17/14
TOTAL VALUE
$294,871
Email:
[email protected] ♦
♦
Value
Schwab MMF
For a free, no-obligation Portfolio Review contact:
♦
Purchase Return Shares Share Date Since Price Buy
Inception = 5/15/06
Fax: (508) 429-0940
More Info: www.priadvisors.com 2
TOTAL RETURNS (as of 1/31/15)
1Month
2.5%
6Month
1Year
3Year
7.5% 8.3% 54.3%
YTD
2.5%
Domestic Stock Funds — data through 2/20/15 Rank
Con
Mod Ven
Ticker
Fund
1
FDEGX
Fidelity Growth Strategies (1.5%r